Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Altamira TherapeuticsCYTOF -25.79% EV-to-EBIT is -0.20 as of Aug. 03, 2026. The stock has 4 warning signs investors should review. Among 387 Biotechnology companies, Altamira Therapeutics ranks worse than 258397.67% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Altamira Therapeutics's Enterprise Value for the quarter that ended in Jun. 2025 was $1.19 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was $-5.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Altamira Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Altamira Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Altamira Therapeutics's EV-to-EBIT falls into.
Altamira Therapeutics's current Enterprise Value is $1.12 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was $-5.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Altamira Therapeutics (CYTOF) has a EV-to-EBIT of -0.20 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Altamira Therapeutics and its competitors. According to the industry distribution chart, Altamira Therapeutics ranks #999999 out of 387 companies in the Biotechnology industry.
Is Altamira Therapeutics' EV-to-EBIT too high?
Altamira Therapeutics' current EV-to-EBIT is -0.20. Based on the distribution chart, Altamira Therapeutics ranks #999999 out of 387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Altamira Therapeutics' EV-to-EBIT compare to CARM and PTIX?
According to the Biotechnology industry distribution chart, Altamira Therapeutics ranks #999999 out of 387 companies for EV-to-EBIT. This places Altamira Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 12.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.63, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Altamira Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Altamira Therapeutics's current EV-to-EBIT is -0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (CYTOF) has a current EV-to-EBIT of -0.20. The current EV-to-EBIT is -0.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Altamira Therapeutics (CYTOF), the current EV-to-EBIT is -0.20 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYTOF has been successfully added to your 
